Clinical trials: Lower Urinary Tract Symptoms (LUTS)
Benign Prostatic Hyperplasia (BPH)
Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride given for 18 months, including a 1-year double-blind randomized co-administration with either tolterodine ER or placebo in men suffering…
- Trial name
- LUTS (NCT00939120)
- Testing
- Tolterodine ER 4mg, Pre-randomization Dutasteride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Siami, Paul F., M.D.
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott
Overactive Bladder Syndrome
Cyclic Versus Continuous Sacral Neuromodulation for LUTS
This will be a prospective, randomized-controlled multi-site trial comparing cyclic versus continuous sacral neuromodulation (SNM) for OAB.
- Trial name
- NCT06170450
- Testing
- Cyclic SNM, Continuous SNM
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
- Trial name
- NCT00410514
- Testing
- Mirabegron
- Where
- 27 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on…
- Trial name
- NCT00831233
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 33 sites in Germany, Spain and 1 more
- Volunteers
- 42 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia (BPH)
Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02026908
- Testing
- Prostate Artery Embolization
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Lower Urinary Tract Symptoms (LUTS)
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- DELUTS (NCT00947882)
- Testing
- Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 404 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasia
- Trial name
- NCT03055624
- Testing
- Embosphere microparticles for prostate artery embolization
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Diego
Bladder Outlet Obstruction
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
This study is a prospective randomized, open label, controlled, double arm, post-marketing study to compare the treatment efficacy of first-line antimuscarinics and α-blockers monotherapy for men with moderate to severe lower…
- Trial name
- NCT01661621
- Testing
- Detrusitol 4 mg QD, Doxazosin 4 mg QD
- Where
- Taiwan
- Volunteers
- 395 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Benign Prostatic Hyperplasia
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker.
- Trial name
- NCT02431754
- Testing
- Tadalafil, Alpha1 Blocker
- Where
- 9 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Eli Lilly and Company
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
BPH
The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
Benign prostatic hyperplasia (BPH) is a common condition among older men. The efficacy of α1-blockers for treating BPH has been well documented and they are recommended for the treatment of BPH by clinical guidelines.
- Trial name
- NCT00696761
- Testing
- Alfuzosin
- Volunteers
- 232 people
- Sponsor
- Asan Medical Center
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Single-arm, interventional pivotal clinical trial collecting patient data from use of the AQUABEAM System, a personalized image-guided waterjet resection system that utilizes a high-velocity saline stream to resect and remove…
- Trial name
- WATERII (NCT03123250)
- Testing
- Aquablation
- Where
- 16 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- PROCEPT BioRobotics
Erectile Dysfunction, Lower Urinary Tract Symptoms
An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in men with mild lower urinary tract symptoms based upon a change from baseline in erectile function (EF) domain of International…
- Trial name
- NCT00893113
- Testing
- Alfuzosin
- Where
- 4 sites in United States
- Volunteers
- 74 people
- Sponsor
- Chesapeake Urology Research Associates
Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
This non-randomized, interventional study will be conducted in a general practice setting to assess the utility of a benign prostatic enlargement (BPE)/benign prostatic obstruction (BPO) screening tool in conjunction with…
- Trial name
- NCT02757963
- Testing
- Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool
- Where
- 45 sites in France, Germany and 3 more
- Volunteers
- 1,679 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
To investigate the therapeutic effect and safety of celecoxib adding on doxazosin and the potential predictive value of the absence of prostate cancer in the treatment of patients with LUTS/BPH and an elevated serum PSA level.
- Trial name
- NCT01678313
- Testing
- Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD)
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Nocturia Associated With Nocturnal Polyuria
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin…
- Trial name
- NCT00902265
- Testing
- desmopressin
- Where
- 140 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals